Commentary on: Pre‐clinical platforms to study therapeutic efficacy of human γδ T cells

Abstract

Abstract This commentary describes chimeric antigen receptors (CAR)‐T cells' impact on solid tumors using novel preclinical models. In haematological malignancies, CAR‐T therapy has had a lot of success. Unfortunately, due to the complex tumour microenvironment (TME) within a solid tumour and the lack of a preclinical model that can recreate this TME complexity, this treatment for solid tumors has failed. Lingling et al., 2022, documented four melanoma organoid models that address many of the significant TME clinical concerns with CAR‐T therapy in solid tumors and observed that γδ T cells treatment in combination with checkpoint inhibitors could significantly improve its infiltration as well as efficacy.

Keywords

• CAR‐T therapy
• human γδ T cells
• patient‐derived T cells
• tumour microenvironment